Are there clinical features that would lead you to consider combining SBRT + immunotherapy in a high risk early stage NSCLC?  

I currently only use SBRT + immunotherapy in medically inoperable, early-stage NSCLC on clinical trial, as it is not yet a standard of care for early-stage disease. There are several randomized phase 3 trials currently testing immunotherapy in this patient population, however. On SWOG/NRG S1914...